Correcting the Risk-Tier Myth in Guatemalan Device Classification

1. Key takeaways

Describing the Class I–IV system in Guatemala as four risk tiers running from low risk to high risk is inaccurate. The official classification table in Annex 1 of NT-37 rests on only two determinative dimensions — site of use (external or internal) and sterile status (non-sterile or sterile) — and the four classes are simply the combinations of these two dimensions. The widely circulated claim that Class I means low risk while Class IV means high-risk implants has no corresponding wording anywhere in the official Annex 1, and classifying by that assumption will lead directly to errors. The sole basis for device classification is NT-37 Article 12 together with Annex 1, and for reagents NT-40 Article 3. Correcting this one misreading before any dossier work starts prevents a cascade of wrong decisions about testing, samples and timeline. The confusion is understandable, because four numbered tiers resemble the risk classes used elsewhere, and many summaries of the Guatemalan system import that framing without checking the source.

2. Legal basis

The provisions that carry the classification logic, and the exact wording they use, are set out below. The Spanish phrasing quoted here is what a reviewer will match against, so keeping it verbatim in internal reports avoids unnecessary interpretation questions during review.

For comparison: Article 3 of NT-40 sets up a separate three-tier Categoría I / II / III of sanitary risk (riesgo sanitario) for in vitro diagnostic reagents, and it is there — and only there — that the official text actually uses risk language.

3. Expert insights

Insight one: one set of numbers, two logics. Devices use Clase I–IV (use times sterility), while reagents use Categoría I–III (sanitary risk). The official texts deliberately use different words — Clase and Categoría — and this is not a matter of translation. Mixing the two terms will push a reagent product into the device channel or the reverse, and the consequences surface only when the dossier is rejected or the wrong testing regime is applied. Auditors and reviewers read the terminology as evidence of whether the applicant understood the scheme at all.

Insight two: risk language in Guatemala appears only in the reagent standard. Article 3 of NT-40 states expressly that the classification is based on the riesgo sanitario, and defines Categoría III as covering blood donor screening, transplant immunocompatibility and the diagnosis of highly infectious diseases. The device standard contains no corresponding risk-tier description, which shows that the regulatory thinking for the two product types is itself different. For devices the law asks where the product is used and how it is supplied; for reagents it asks what harm a wrong result could cause. A file prepared with the wrong question in mind will be coherent internally but wrong in substance.

Insight three: the misreading has real consequences. Under the assumption that Class IV means highest risk and therefore active implants, an ordinary urinary catheter for internal use in sterile supply would be misjudged as the top level, while a sterile external surgical gown would be placed at only the second tier — which in these two cases happens to match the Annex 1 combination table; but if the risk assumption is used in reverse to derive classes for products not in the example table, the result will conflict with the official combination table, and the error then shows up in the testing obligation.

Insight four: the testing obligation follows the decision axis. Annex 1 writes whether testing is required directly beneath each class: Class I is exempt, and the other three classes are tested. Once the decision axis is applied wrongly, the testing schedule, the sample quantities and the compliance cost all go wrong with it. This is why the myth matters more than a terminology debate: the money follows the axis, not the label. A project that classifies correctly on day one carries no hidden testing contingency; one that classifies by risk intuition discovers the error only after samples have been reserved and slots booked.

4. Practical recommendations

• Use Clase for devices and Categoría for reagents consistently in internal documents, without interchanging them.
• Quote the table header structure of Annex 1 directly in classification reports, and cite no risk-level description at all.
• Run one session of decision-axis training for teams newly entering the market, focused on correcting the preconception of four risk tiers.
• Derive borderline products from the two-by-two combination, and state the answers for both dimensions in the report, so the reviewer can reproduce the result from the official table alone.
• Before citing any external source, compare it with the original text of Annex 1; wherever they disagree, the official text governs, and the discrepancy is noted in the file.

5. Verification checklist

• □ Internal documents distinguish Clase (devices) from Categoría (reagents)
• □ The classification report contains no risk-tier wording
• □ The class was derived from external or internal times sterile or non-sterile
• □ The testing obligation was confirmed per the class
• □ External cited material has been compared with the original Annex 1 text

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com